MYC/Bcl-2蛋白共表达与弥漫性大B细胞淋巴瘤临床特征的关系及其对预后的影响

Abstract
Figure/Table
References (21)
Related Citation (15)

Download: PDF (550 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To analyze the relationships of MYC/Bcl-2 proteins co-expression of clinical features and prognosis of diffuse large B-cell lymphoma (DLBCL), in order to explore the significance with MYC/Bcl-2 protein co-expression in DLBCL． Methods From January 2012 to January 2014, in Renmin Hospital of Wuhan University, clinical data of 59 DLBCL patients were collected, and the expression of MYC and Bcl-2 protein was analyzed by immunohistochemistry for their pathological tissue samples, the relationships of MYC/Bcl-2 co-expression with clinical features and prognosis were analyzed. Results Among 59 patients, there were 19 MYC/Bcl-2 co-expression patients, accounting for 32.2%． MYC/Bcl-2 co-expression was more easily detected in patients with later stage and higher IPI scores, the differences were statistically significant (P < 0.05). The 5-year OS of MYC/Bcl-2 co-expression patients was 26.3%, it was significantly lower than that of non-co-expressed patients (77.5%), the difference was statistically significant (P < 0.01), the Cox proportional hazards model showed MYC/Bcl-2 co-expression was associated with prognosis (OR = 0.170, 95%CI: 0.077-0.376, P < 0.01). Conclusion MYC/Bcl-2 co-expression is associated with the prognosis of diffuse large B-cell lymphoma.

Key words： Diffuse large B-cell lymphoma MYC/Bcl-2 co-expression Prognosis

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	HUANG Ya′ni GE Wei▲

Cite this article:

HUANG Ya′ni GE Wei▲. Relationships of MYC/Bcl-2 co-expression with clinical features and prognosis of diffuse large B-cell lymphoma[J]. 中国医药导报, 2018, 15(31): 76-79.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2018/V15/I31/76

[1] Kubuschok B，Held G，Pfreundschuh M. Management of diffuse large B-cell lymphoma （DLBCL）[J]. Cancer Treat Res，2015，165:271-288.
[2] Leonard JP，Kolibaba K，Reeves JA，et al. Randomized phase 2 open-label study of R-CHOP ?魦±Bortezomib in Patients（Pts）with untreated non-germinal center b-cell-like （Non-GCB） subtype diffuse large cell lymphoma （DLBCL）：Results from the pyramid trial （NCT00931918）[J]. Clin Adv Hematol Oncol，2016，14（2 Suppl 1）：15-16.
[3] Le GS，Talmant P，Touzeau C，et al. The clinical presentation and prognosis of diffuse large B-cell lymphoma with t（14;18） and 8q24/c-MYC rearrangement [J]. Haematologica，2007，92（10）：1335-1342.
[4] Vardiman JW，Thiele J，Arber DA，et al. The 2008 revision of the World Health Organization （WHO） classification of myeloid neoplasms and acute leukemia：rationale and important changes [J]. Blood，2009，114（5）：937-942.
[5] Lister TA，Crowther D，Sutcliffe SB，et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin′s disease： Cotswolds meeting [J]. J Clin Oncol，1989，7（11）：1630-1636.
[6] Carbone PP，Kaplan HS，Musshoff K，et al. A predictive model for aggressive non-Hodgkin′s lymphoma [J]. NEJM，1993，329（14）：987-994.
[7] Arber DA，Orazi A，Hasserjian R，et al. The 2016 revision to the World Health Organization（WHO）classification of myeloid neoplasms and acute leukemia [J]. Blood，2016， 127（20）：2391-2396.
[8] Hu S，Xumonette ZY，Tzankov A，et al. MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures：a report from The International DLBCL Rituximab-CHOP Consortium Program [J]. Blood，2013，121（20）：4021-4031.
[9] 杨帆，钱申贤，赵亦菲，等.MYC/Bcl-2共表达在弥漫大B细胞淋巴瘤预后判断中的意义研究[J].中华疾病控制杂志，2016，20（7）：717-720.
[10] Kieffer-Kwon KR，Nimura K，Rao S，et al. Myc regulates chromatin decompaction and nuclear architecture during B cell activation [J]. Mol Cell，2017，67：1-13.
[11] De DM，Porazzi P，Soliera AR，et al. Targeting CDK6 and BCL2 exploits the “MYB addiction” of Ph+ acute lymphoblastic leukemia [J]. Cancer Res，2017，3（2）：181-186.
[12] Buendia MA，Bourre L，Cairo S. Myc target mirs and liver cancer： small molecules to get myc sick [J]. Gastroenterology，2012，142（2）：214-218.
[13] 张兴艳，马志萍，崔文丽，等.PRDM1基因失活对C-MYC的调控在弥漫性大B细胞淋巴瘤中的作用[J].中华病理学杂志，2018，47（1）：25-31.
[14] Mcconnell I，Anderson E，Yazbeck V. Abstract 2770： Bcl-2 overexpression is a predictive biomarker for the combination of ABT-199 with chemotherapy in diffuse large B-cell lymphoma cell lines [J]. Cancer Res，2017，77（13 Suppl）：2770-2773.
[15] Bischin AM，Dorer R，Aboulafia DM. Transformation of follicular lymphoma to a high-grade B-cell lymphoma with MYC and BCL2 translocations and overlapping features of burkitt lymphoma and acute lymphoblastic leukemia： a case report and literature review [J]. Clin Med Insights Blood Disord，2017，10：1179545X-17692544X.
[16] Patra■cu AM，Rotaru I，Olar L，et al. The prognostic role of Bcl-2，Ki67，c-MYC and p53 in diffuse large B-cell lymphoma [J]. Rom J Morphol Embryol，2017，58（3）：837-843.
[17] Oki Y，Noorani M，Lin P，et al. Double hit lymphoma：the MD Anderson Cancer Center clinical experience [J]. Br J Haematol，2014，166（6）：891-901.
[18] Petrich AM，Gandhi M，Jovanovic B，et al. Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma：a multicenter retrospective analysis [J]. Blood，2016，124（15）：2354-2361.
[19] Staiger AM，Ziepert M，Horn H，et al. Clinical impact of the cell-of-origin classification and the MYC/ BCL2 dual expresser status in diffuse large B-Cell lymphoma treated within prospective clinical trials of the German high-grade non-Hodgkin's lymphoma study group [J]. J Clin Oncol，2017，35（22）：2515-2526.
[20] Green TM，Young KH，Visco C，et al. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide，doxorubicin，vincristine，and prednisone [J]. J Clin Oncol，2012，30（28）：3460-3467.
[21] Miranda RN，Khoury JD，Medeiros LJ. B-Cell Lymphoma，Unclassifiable，with features intermediate between diffuse large B-cell lymphoma and burkitt lymphoma [J]. Br J Haematol，2013，162（1）：40-49.